Neurokinin (NK) 1 Antagonist for Pathological Aggression for Harmful, Impulsive, and Self-/Aggressive Behaviour
Status:
Unknown status
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
Neurokinin (NK) -1 antagonist will be administered to study patients in a double-blind
placebo trial. Patients receive assessments including Anger Disorder Scale (ADS) and Modified
Overt Aggression Scale (MOAS) and perform computerized study tasks during MRI before the
trial begins. Patients receive either one week of the drug or one week of placebo and perform
the same tasks and assessments. Then patients receive another week of the alternate pill,
followed by another round of tasks during MRI and assessments.